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Background: Diabetic nephropathy is a growing clinical problem, and the cause for >40% of incident ESRD cases.
Unfortunately, few modifiable risk factors are known. The objective is to examine if albuminuria and history of
diabetic nephropathy (DN) in a sibling are associated with early DN progression or mortality.
Methods: In this longitudinal study of adults >18 yrs with diabetes monitored for up to 9 yrs (mean 4.6 ± 1.7 yrs),
435 subjects at high risk (DN family history) and 400 at low risk (diabetes >10 yrs, normoalbuminuria, no DN family
history) for DN progression were evaluated for rate of eGFR change using the linear mixed effects model and
progression to ESRD. All-cause mortality was evaluated by Kaplan-Meier analyses while controlling for baseline
covariates in a Cox proportional hazards model. Covariates included baseline eGFR, age, gender, race, diabetes
duration, blood pressure, hemoglobin A1c and urine albumin:creatinine ratio. Propensity score matching was used
to identify high and low risk group pairs with balanced covariates. Sensitivity analyses were employed to test for
residual confounding.
Results: Mean baseline eGFR was 74 ml/min/1.73 m2 (86% of cohort >60 ml/min/1.73 m2). Thirty high risk and no
low risk subjects developed ESRD. eGFR decline was significantly greater in high compared to low risk subjects.
After controlling for confounders, change in eGFR remained significantly different between groups, suggesting that
DN family history independently regulates GFR progression. Mortality was also significantly greater in high versus
low risk subjects, but after controlling for baseline covariates, no significant difference was observed between
groups, indicating that factors other than DN family history more strongly affect mortality. Analyses of the matched
pairs confirmed change in eGFR and mortality findings. Sensitivity analyses demonstrated that the eGFR results
were not due to residual confounding by unmeasured covariates of a moderate effect size in the propensity
matching.
Conclusions: Diabetic subjects with albuminuria and family history of DN are vulnerable for early GFR decline,
whereas subjects with diabetes for longer than 10 years, normoalbuminuria and negative family history, experience
slower eGFR decline, and are extremely unlikely to require dialysis. Although we would not recommend that
patients with low risk characteristics be neglected, scarce resources would be more sensibly devoted to vulnerable
patients, such as the high risk cases in our study, and preferably prior to the onset of albuminuria or GFR decline.
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Diabetes is a burgeoning public health problem, with
an estimated prevalence of 25.8 M children and adults
in the U.S. (http://www.diabetes.org/diabetes-basics/
diabetes-statistics/). Diabetic nephropathy (DN) is one
of the most feared complications, and the etiology for
over 40% of incident end stage renal disease (ESRD)
cases in the U.S. Since only a minority of diabetic
patients develop DN, it is important to identify the at-
risk population, prior to GFR decline.
Hyperfiltration is the earliest measurable biomarker
for DN progression in types 1 and 2 diabetes. However
in type 2 diabetes, which comprises the vast majority of
DN, the mean duration between disease onset and diag-
nosis commonly exceeds the window for hyperfiltration
detection [1]. Microalbuminuria is a practical alternative,
but its reliability as a predictor of DN progression has been
questioned, due to frequent reversion to normoalbuminuria
[2], and the occurrence of typical DN histopathology in
the absence of albuminuria [3,4]. Intensive effort is
therefore being invested to identify more reliable
biomarkers.
Microalbuminuria is, however, an accepted risk factor
for all-cause and cardiovascular mortality [5]. Since esti-
mated GFR (eGFR) and the rate of eGFR decline are also
associated with mortality [6-10], staging systems, which
combine proteinuria and eGFR, have been proposed for
identification of the highest risk population for death
and ESRD [10,11]. Although these strategies provide an
efficient mechanism for screening large populations,
they tend to focus on advanced disease, which may not
be as amenable to therapies.
Because DN is heritable [12], we have advocated that
diabetic siblings should be vigilantly targeted for reduc-
tion of modifiable risks for DN progression, such as
blood pressure and glycemia [13]. Early therapeutic
intervention, before GFR and albuminuria are grossly
abnormal, is desirable, but whether DN family history is
a discriminator in this subpopulation is unclear. To
examine the hypothesis that DN family history and albu-
minuria predict early DN progression, we have assem-
bled a longitudinal cohort of diabetic subjects, with
relatively preserved baseline GFR, who were evaluated
for rate of eGFR change, progression to ESRD, and mor-
tality, after adjusting for relevant covariates.
Methods
Study participants
The study design has been described [13]. Briefly, high
risk subjects were defined as diabetic siblings to patients
with ESRD due to DN (i.e., DN family history). A dis-
tinction between type 1 and 2 diabetes was not made,
though based upon mean age at diabetes diagnosis
>40 years, the cohort is presumed to be almost entirelytype 2. Exclusion criteria included eGFR <20 mL/min/
1.73 m2, chronic dialysis or renal transplantation. Low
risk subjects were defined by diabetes >10 years, urine
albumin:creatinine ratio <30 mg/g at study entry, and
absence of ESRD family history in first or second degree
relatives.
Participants were enrolled beginning April 1, 2003,
monitored annually for eGFR through June 30, 2011,
and for mortality through March 31, 2012. Annual eval-
uations included a standardized questionnaire for demo-
graphic and medical information. Sitting BP, measured
at the brachial artery with a manual sphygmomanom-
eter, was recorded by research nurses.
The study protocol was approved by the Institutional
Review Boards at Case Western Reserve University affili-
ated hospitals (MetroHealth System, University Hospitals
Case Medical Center, Louis Stokes Cleveland VA Medical
Center) and Wake Forest University, and all subjects
provided written consent for enrollment.Serum creatinine assay
Serum creatinine was measured as described [13]. Begin-
ning May 20, 2007, creatinine assays used isotope dilution
mass spectrometry (IDMS)-traceable reagent methods.
Forty serum specimens spanning the range of creatinine
concentrations were re-assayed with the Cleveland Clinic
Laboratory reference standard assay to assess precision
(Additional file 1: Figure S1).Cystatin C assay
Serum cystatin C was measured from stored frozen sam-
ples by a particle-enhanced immunonephelometric assay
(N Latex Cystatin C, Siemens Healthcare Diagnostics,
Deerfield, IL) with a BNII nephelometer (Siemens) at the
University of Minnesota. To avoid assay drift over time,
all samples were assayed within a 30-day period.Albumin assay
Urine albumin concentration was initially determined by
radioimmunoassay as described [13]. This assay was
discontinued in 2007, and thereafter urine albumin was
assayed by a turbidometric method with a Beckman
Coulter LX20 analyzer. Assays on 20 randomly selected
samples by both methods revealed that no calibration
correction was required.Urine creatinine assay
Urine creatinine concentration was determined as de-
scribed [13].Hemoglobin A1c (HbA1c) assay
HbA1c assays were performed as described [13].
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eGFR based on serum creatinine (eGFRcreat) was calculated
from the MDRD Study equations: eGFRcreat (mL/min/
1.73 m2) = 186 × creatinine (mg/dL)−1.154 × age−0.203 × 0.742
(if female) × 1.212 (if African American) prior to May 20,
2007 [14], or eGFRcreat (mL/min/1.73 m
2) = 175 × cre-
atinine (mg/dL)−1.154 × age−0.203 × 0.742 (if female) ×
1.212 (if African American) after May 20, 2007 [14]. For
eGFR calculations based upon serum creatinine plus
cystatin C values (both in mg/dl), we used the modified
CKD-EPI equation, eGFRcreat+cysC (mL/min/1.73 m
2) =
177.6 × creatinine-0.65 × [-0.105 + (1.13 x CysC)]-0.57 ×
age-0.20 × (0.82 if female) × (1.11 if black) [14]. For calcu-
lations based upon standardized cystatin C only, we used
the CKD-EPI equation eGFRcysC (mL/min/1.73 m
2) =
127.7 × [-0.105 + (1.13 × CysC)]-1.17 × age-0.13 × (0.91 if
female) × (1.06 if black) [14].
Since samples assayed for cystatin C assays repre-
sented a subset (56%) of the samples assayed for creatin-
ine, to account for missing values, we imputed plausible
eGFRcysC and eGFRcreat+cysC values to match eGFRcreat
observations using PROC MI in SAS Version 9.2. Mul-
tiple imputations were performed, creating five data sets
for valid inference using the Markov Chain Monte Carlo
algorithm [15]. After running separate mixed effects
models for each imputed data set, we used PROC
MIANALYZE to combine the results.
Statistical analyses for risks of DN progression
We compared risk group differences in baseline charac-
teristics, eGFR and mortality via chi-square, t-tests and
Wilcoxon rank-sum tests. The linear mixed effects
model [16] was used to evaluate the mean change in
eGFR (by all equations) between high and low risk sub-
jects. This model is an extension of linear regression for
longitudinal data, and is specifically designed to handle
correlated repeated measurements, missing data and
dropouts. The baseline covariates that were adjusted in
our models included age, gender, race, systolic BP, dia-
stolic BP, HbA1c, diabetes duration, eGFR, and urine al-
bumin:creatinine ratio. Longitudinal models including
these baseline covariates assessed whether eGFR change
is: (1) different in the high and low risk groups (risk
group by time interaction effect), (2) constant over time
[time effect (years)], and (3) different between risk
groups under the assumptions that the eGFR values dif-
fer (i.e., at baseline) and progression curves remain par-
allel (group main effect), while controlling for covariates.
The interaction between risk group and time, depicted
by β, in the unadjusted models describes eGFR slope
differences in high vs. low risk groups. In the covariate
model, the interaction, depicted by βBasic, adjusts for
baseline covariates in order to describe the impact of
family history on eGFR change. Propensity scoretechniques were used to identify matched sets of pa-
tients from the high and low risk groups with similar
baseline covariate distributions [17,18]. We used a logis-
tic regression model to estimate propensity to be a high
risk subject based on all baseline covariates: age, gender,
race, diabetes duration, systolic BP, diastolic BP, HbA1c,
eGFRcreat, and urine albumin:creatinine ratio. Sensitivity
analysis was then used to determine the impact of re-
sidual confounding in the matched pair subsample [18].
As an alternative renal outcome to eGFR decline, we
also compared the number of high versus low risk subjects
that progressed to ESRD. A separate analysis was also
undertaken to assess the effect of albuminuria on eGFR
decline, using the linear mixed effects model. This analysis
was conducted in high risk subjects only, because low risk
subjects required normoalbuminuria upon enrollment.
The effects of 30 mg/g (microalbuminuria) and 300 mg/g
macroalbuminuria) thresholds were tested in the model.
Statistical analyses for mortality
Every study subject was evaluated for date of death by a
Social Security Death Index database search (www.
genealogybank.com/gbnk/ssdi/). Mortality data were an-
alyzed to compare time until death between risk groups
using a Kaplan-Meier plot and log-rank test for un-
adjusted analyses. A Cox proportional hazards model
also included the baseline covariates age, gender, race,
systolic BP, diastolic BP, HbA1c, diabetes duration, base-
line eGFR, and urine albumin:creatinine ratio to exam-
ine the effect of DN family history on risk of death [19].
Eighty-seven per cent of subjects in the low risk group
and 74% of subjects in the high risk group were right
censored.
We also ran an extended Cox regression model to esti-
mate the hazard risk, including all the covariates, but
the baseline measurements were replaced with the an-
nual measurements for systolic BP, diastolic BP, HbA1c
and urine albumin:creatinine ratios. This analysis used
data from the first seven repeated measures, as add-
itional data were too sparse (n = 16 for each of the four
time-varying covariates at the eighth repeated measure).
We used the counting process style of input in PROC
PHREG in SAS Version 9.2 to handle the time-varying
covariates in the extended Cox regression model [20].
Finally, a Cox proportional hazards model was applied
to the high and low risk groups matched for baseline co-
variates, which were then stratified by the matched pairs,
to evaluate if risk group had an effect on mortality after
reducing the impact of selection.
Results
Patient characteristics
Diabetic subjects were segregated according to high
and low risk for DN as defined in Methods. Baseline
Figure 1 Unadjusted eGFR change over time. Linear regression
of eGFRcreat was plotted against time. Shaded areas represent 95%
confidence intervals. The two regression lines are significantly
different (p <0.001).
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74 ml/min/1.73 m2 for the cohort, and 86% of subjects
had eGFR >60 ml/min/1.73 m2 at study inception, indicat-
ing that progression rates were calculated from a pre-
served baseline GFR in most instances. Of factors that
differed significantly between risk groups, diabetes dur-
ation and albuminuria were anticipated, based upon risk
group definitions. Use of lipid-lowering agents (predomin-
antly statins) was also greater in the low risk group. Base-
line information for each group was calculated according
to recruitment center (Case Western Reserve University,
Wake Forest University). Because few between-center
differences were observed (Additional file 1: Table S1),
data are combined in all subsequent analyses.
Risks for DN progression
Strikingly, 30 high risk and no low risk subjects developed
ESRD. The unadjusted, annualized eGFRcreat change
was significantly different between risk groups (Figure 1,
β = -1.65, p <0.001). The difference in eGFRcreat+cysC
(β = -0.97, p = 0.10) and eGFRcysC (β = -0.62, p = 0.40)
change between risk groups was not statistically significant
(not shown). Equations to describe mean change of
eGFRcreat also demonstrate greater decline in high riskTable 1 Baseline characteristics by risk group
High risk Low risk p-value
N 435 400
Gender (% female) 62.8 67.0 0.20
Age (yr) 58.9 ± 10.5 59.9 ± 11.8 0.20
Race (% AA) 51.4 52.5 0.75
Diabetes duration (yr) 14.1 ± 9.7 17.2 ± 8.7 < 0.01
HbA1c (%) 7.7 ± 1.9 7.8 ± 2.0 0.46
Systolic BP (mm Hg) 135.4 ± 17.8 134.2 ± 19.7 0.36
Diastolic BP (mm Hg) 75.9 ± 11.6 74.7 ± 11.9 0.14
Serum creatinine (mg/dl) 1.05 ± 0.37 0.97 ± 0.25 <0.01
eGFRcreat (ml/min/1.73 m
2) 74.3 ± 27.7 76.1 ± 24.3 0.32
Serum cystatin C (mg/dl) 1.1 ± 0.3 1.0 ± 0.5 <0.01
eGFRcreat+cysC (ml/min/1.73 m
2) 73.9 ± 29.3 77.4 ± 24.1 0.06
Urine alb:creat (mg/g) 27.6 (9-119) 11.2 (6-22) <0.01
BP meds (%) 77.7 81.6 0.16
ACE inhibitor (%) 48.5 52.8 0.21
ARB (%) 14.1 14.8 0.77
Other BP meds (%) 57.3 57.4 0.98
Insulin (%) 45.8 42.9 0.26
Oral hypoglycemic agents (%) 61.0 65.6 0.06
Lipid-lowering agents (%) 64.2 70.2 0.01
Data are presented as mean ± standard deviation for continuous measures, %
frequency of reference level for discrete measures and median (first quartile-
third quartile) for urine alb:creat (mg/g). Analyses to generate p-values include
t-tests, χ2 tests and Wilcoxon rank-sum tests where appropriate. Abbreviations:
ACE, angiotensin converting enzyme; alb:creat, albumin to creatinine ratio;
ARB, angiotensin receptor blocker; BP, blood pressure; GFR, glomerular
filtration rate; HbA1c, hemoglobin A1c.[eGFRcreat = (-2.19 × years) + 73.29, in ml/min/1.73 m
2],
compared to low risk [eGFRcreat = (-0.78 × years) + 75.16,
in ml/min/1.73 m2] subjects.
A significant association was observed between eGFRcreat
change and baseline eGFRcreat, albuminuria, HbA1c, sys-
tolic and diastolic blood pressure in a mixed effects model
(Table 2). As an alternative means of assessing a difference
in eGFR between high and low risk groups, a partial re-
gression plot was constructed, whereby the plot displayed
the relationship of eGFR against time, after adjusting for
the significant baseline covariates. Figure 2 reveals that
eGFRcreat decline remained significantly greater in the high
risk group (βBasic = -1.74, p <0.001). An analogous model
for eGFRcreat+cysC showed significant associations with
baseline eGFRcreat+cysC and albuminuria only (Additional
file 1: Table S2), and following adjustment eGFRcreat+cysC
decline was still significantly greater for high risk subjects
(βBasic = -1.38, p = 0.001). After accounting for covariates,
the remaining variable that distinguishes the high and low
risk groups is family history of DN. Therefore, persistent
differences in rate of eGFR decline between risk groups,
after covariate adjustment, suggest that DN family history
is a factor in the progression of DN.
Using a greedy matching algorithm for propensity
matching on the propensity scores from the logistic re-
gression model, covariates were more similar between
risk groups within the matched pair subsample (Figure 3,
N = 199 pairs), thus reducing the impact of selection in
the subsample. Using only matched subjects with ≥3
eGFRcreat measurements (N = 155) we estimated indi-
vidual slopes for eGFRcreat in a linear regression model,
by regressing eGFRcreat against year for each individual.
Significant differences in individual estimated slopes by
risk group for the matched pairs were observed (p <0.001,
by non-parametric Wilcoxon signed-rank test). These data
Table 2 Baseline covariate effects on eGFRcreat using
linear mixed effects model parameter estimates, 95%
confidence intervals and p-values
Effect Estimate (βBasic) 95% CI p-value
Risk group (high vs. low) 1.57 (-1.49, 4.63) 0.313
Year -0.93 (-1.34, -0.52) <0.001
Risk group by year
interaction
-1.74 (-2.56, -0.92) <0.001
Diabetes duration 0.02 (-0.08, 0.12) 0.708
eGFRcreat 0.73 (0.69, 0.77) <0.001
Urine albumin:creatinine
ratio
-4.40 (-6.09, -2.71) <0.001
Systolic BP -0.08 (-0.14, -0.02) 0.010
Diastolic BP 0.13 (0.03, 0.23) 0.010
HbA1c -0.65 (-1.30, 0.00) 0.046
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the high risk group, and imply that family history of DN is
a factor in the progression of DN.
A sensitivity analysis was performed to examine the
degree of hidden bias that would be necessary to explain
the observed association between eGFR decline and risk
group in the 155 matched pair subset. We determined
that a hidden bias or unaccounted covariate would needFigure 2 Partial regression plot of eGFR progression. A linear
regression model approach was used to generate a partial
regression plot for eGFRcreat, adjusting for covariates shown in
Table 2. Shaded areas represent 95% confidence intervals. The plot is
derived from several different regression equations. Initially, the
residual errors of a regression equation were obtained, with (1) eGFR
as the outcome, and all covariates besides years, as the independent
variables, and (2) years as the outcome against all other covariates as
the independent variables. These two steps were conducted
separately for the high and low risk groups, and the resulting
residual errors were then plotted against each other. Note that
values on both axes are residuals, rather than actual eGFRcreat values.
Furthermore, because analyses were conducted separately for high
and low risk groups, by definition, both lines intersect at the graph
origin (0,0). The high and low risk groups are significantly different
(βBasic = -1.74, p <0.001).to cause an increase of the slope differences in high vs.
low risk groups by more than 50%. Therefore, the asso-
ciation cannot be attributed to hidden biases or unmeas-
ured covariates with only small effects.
Albuminuria as a biomarker for DN progression
One criterion that distinguishes high and low risk
groups is absence of microalbuminuria in the low risk
group. To further evaluate the role of albuminuria on
GFR decline, we employed a linear mixed effects model,
considering both macroalbuminuria (>300 mg/g urine
albumin: creatinine ratio) and microalbuminuria (30-
299 mg/g) thresholds. Decline in eGFRcreat was signifi-
cantly greater in subjects above the 300 mg/g threshold
(p < 0.01), while the 30 mg/g threshold showed a trend to-
ward larger decline (p = 0.054). The correlation between
albuminuria and change in eGFRcreat+cysC or eGFRcysC was
not significant.
Risks for mortality
Over the duration of the study, 119 high risk and 54 low
risk subjects died. The Kaplan-Meier plot of cumulative
risk of death in high versus low risk subjects is shown in
Figure 4 (Log-rank test χ2 = 20.41, p <0.001). There was
a trend toward faster DN progression in those who
died, as shown by the unadjusted (β = -0.03, p = 0.089)
and baseline covariate-adjusted eGFRcreat (βBasic = -2.00,
p = 0.094) change over time.
However, using a Cox proportional hazards model,
after correcting for the confounding effects of albumin-
uria, baseline eGFR, age, gender, race, diabetes duration,
BP, and HbA1c, the difference in time until death be-
tween the high and low risk groups was no longer statis-
tically significant (Table 3). The results suggest that the
significant covariates, albuminuria, age, and gender
(Table 3) exert more pronounced effects, compared to
DN family history, upon mortality.
After using an extended Cox regression model to cor-
rect for the confounding effects of baseline eGFR, age,
gender, race, and diabetes duration, and the repeated
measures of albuminuria, BP, and HbA1c, the difference
in time until death between the high and low risk groups
was also not statistically significant (hazard ratio = 1.06,
95% CI 0.73,1.53). Similar results were found as in
Table 3 for all baseline covariates along with the time-
varying counterparts of albuminuria, BP, and HbA1c.
The results verify the findings of Table 3, suggesting that
the significant covariates, albuminuria, age, and gender,
exert greater effects, compared to DN family history,
upon mortality.
Application of a Cox proportional hazards model on
the 199 matched pairs (based on propensity score),
stratifying by the matched pairs, revealed that risk group
still had no significant effect on mortality after reducing
Figure 3 Plot of effect sizes (difference in means divided by the standard error) comparing propensity to be a high risk subject and
covariate differences between risk groups before and after propensity matching. An effect size ≤ 0.20 (at the dashed line) represents a
relatively small difference between risk groups on the propensity score or covariate.
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2.47). We excluded three subjects from our survival
analyses that died during the study, but no date of death
was recorded. Conclusions were unchanged when logistic
regression was performed to include these three additional
subjects, treating all-cause mortality as binary.
Discussion
In contrast to some large, longitudinal trials of CKD,
which exclude subjects with stage 1 or 2 disease [21,22],
our cohort was enriched for patients with preserved
GFR, which enabled identification of progression risk
factors that might be more amenable to therapeutic
intervention. The diabetic subjects with low risk group
characteristics (diabetes >10 years, absence of albumin-
uria and family history of ESRD) did not progress to
ESRD during the course of the study. After covariate
adjustment by multiple methods, we found that high risk
subjects developed faster eGFR decline compared to low
risk subjects, implying that DN family history regulatesFigure 4 Kaplan–Meier curves for mortality in the high and low risk gDN progression. GFR decline is customarily depicted to
occur 15-25 years after diabetes onset, and following the
appearance of overt proteinuria [23]. Although macroal-
buminuria was identified as an independent risk for DN
progression in our study, eGFR decline was noted when
most patients were micro- or normoalbuminuric, and
often less than 10 years after diabetes onset.
Several studies have identified family history as a risk
for DN progression [24,25], or ESRD due to DN [26]. A
unique feature of our study is that history of DN in a
sibling predicted early GFR decline, when GFR is rela-
tively preserved, and therapeutic benefit is more likely.
The independent effect of family history on eGFR de-
cline suggests that genetic variants regulate DN progres-
sion. Intensive efforts are ongoing to identify the
multiple, relevant genetic variants for DN [27], and it
remains to be determined whether the same genes
affect early DN, characterized by microalbuminuria,
eGFR changes in the upper register, and modest histo-
logical alterations, versus late DN progression, whichroups (p <0.001).
Table 3 Effect of risk group and baseline covariates on
time until death in a Cox proportional hazards model
after adjusting for all covariates
Effect Hazard ratio 95% CI p-value
Risk group (high vs. low) 1.17 (0.73, 1.89) 0.521
Age 1.06 (1.04, 1.09) <.001
Gender (male vs. female) 1.99 (1.28, 3.09) 0.002
Race (non-white vs. white) 1.52 (0.95, 2.43) 0.078
Diabetes duration 1.00 (0.99, 1.02) 0.829
eGFR creat 0.99 (0.99, 1.00) 0.273
Urine alb:creat ratio 1.28 (1.10, 1.50) 0.002
Systolic BP 1.00 (0.99, 1.01) 0.857
Diastolic BP 1.01 (0.99, 1.03) 0.373
HbA1c 1.10 (0.98, 1.24) 0.104
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profound GFR decline, and significant glomerular and
interstitial fibrosis. Our dataset is one of the few that
could serve as a validation cohort for early DN in type
2 diabetes.
We anticipated that DN family history might also cor-
relate with death, and although there was an association
with unadjusted mortality, this hypothesis was not sup-
ported by multiple statistical approaches that adjusted
for covariates. Because of the divergent correlations be-
tween DN progression and mortality with family history,
we speculate that different genetic variants may control
these two phenotypes. The lack of association between
DN family history and mortality is consistent with work
by Freedman et al, which showed that diabetic dialysis
patients with a family history of ESRD are not more
likely to die than those without a family history [28].
Decreased GFR is associated with both ESRD and pre-
ESRD mortality, though most studies have not focused
on subjects with DN [6-8]. In diabetic patients, the risk
for competing ESRD and mortality outcomes depends
on study population characteristics, most notably
baseline GFR. Several recent reports in subjects with
macroalbuminuria and varied GFR at enrollment con-
cluded that ESRD is relatively more common [29-31].
These data are in contrast to UKPDS and Joslin Clinic
studies, which demonstrated greater incidence of death
compared to ESRD in patients with type 2 diabetes
[32,33]. Our cohort experienced 21% mortality over the
course of the study, and we observed a greater likeli-
hood of death than progression to ESRD, and a trend
toward faster eGFR decline in subjects who died.
One caveat to the earlier trials demonstrating greater
relative mortality is that patients were enrolled in an era
when advanced cardiovascular interventions and pharma-
cologic agents, e.g., ACE inhibitors and ARBs, were not
routinely administered. However, in our observational
cohort, two-thirds of subjects received ACE inhibitors orARBs, reflecting contemporary standards of care. Further-
more, the mean rate of eGFR decline for the entire study
population was 1.5 ml/min/1.73 m2/yr, and only 2.2 ml/
min/1.73 m2/yr in the high risk group, which is lower than
other DN trials [9].
One limitation of this study is that GFR was not dir-
ectly measured. Although iothalamate clearances are
considered to be the standard, assay variability is prob-
lematic [34], and values weakly associate with CKD
complications [35]. More importantly, measured GFR is
impractical for large, longitudinal trials. We therefore
opted for eGFR calculations, which accurately predict
clinical outcomes [8]. Because GFR estimating equations
were generated from subjects with renal dysfunction,
MDRD- or CKD-EPI-derived eGFR values tend to
underestimate GFR in the >60 ml/min/1.37 m2 register
in cross-sectional analyses. However, this bias is less
with longitudinal measurements, and a recent large trial
concluded that eGFR change over time is a reliable
measure of CKD progression [36]. To enhance robustness
of the analyses, we compared eGRFcreat, eGRFcreat+cysC and
eGFRcysC between risk groups. The data showed differ-
ences between groups, most reliably with eGRFcreat, to a
lesser extent with eGRFcreat+cysC, and not with the
eGFRcysC equation. One explanation for this discrep-
ancy is that our cohort had fewer samples assayed for
cystatin C than creatinine. Furthermore, analyses using
eGRFcreat+cysC required imputation of missing values,
which may weaken the correlation [37].
Other potential weaknesses of the study design include
discrete entry criteria for high and low risk groups,
which may limit conclusions to patients with similar
characteristics, rather than the general population. Pro-
pensity score matching has inherent limitations, such as
the choice of finite co-variates, which creates the possi-
bility that relevant co-variates could be omitted. How-
ever, we included the major co-variates associated with
most DN studies, and the results of our sensitivity ana-
lyses revealed that results were unlikely to be attributed
to co-variates with small effect sizes. The propensity
matched samples represented a subset of the entire
population, so the smaller sample size may therefore
reduce power. Annual measurements for systolic BP, dia-
stolic BP, HbA1c and urine albumin:creatinine ratios
were collected. However, these time-varying covariates
have the potential for measurement error and a false attri-
bution to cause, if the predictor variable is associated with
the error term. We note these potential limitations, which
we address using the counting process style of input, when
evaluating our extended Cox model with these time-
varying covariates. However, because of these potential
biases, we could not incorporate these covariates into our
mixed effects models. Instead, we are applying joint model
methodology to examine the longitudinally measured
Gunzler et al. BMC Nephrology 2013, 14:124 Page 8 of 9
http://www.biomedcentral.com/1471-2369/14/124covariates and eGFR (DG, AS, and JS, manuscript in
preparation).
Conclusions
In our diabetic cohort with mean eGFR = 74 ml/min/
1.73 m2 albuminuria and family history of DN are
significant risks for GFR decline and progression to
ESRD, whereas subjects with diabetes for longer than
10 years, normoalbuminuria and negative family history,
experience slower eGFR decline, and are extremely un-
likely to require dialysis. Although we would not recom-
mend that patients with low risk characteristics be
neglected, scarce resources would be more sensibly de-
voted to vulnerable patients, such as the high risk cases in
our study, and preferably prior to the onset of albuminuria
or GFR decline.
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B, Bland-Altman plot measuring the difference between the two assay
values for each sample (Y-axis) versus mean values between samples
(X-axis). Table S1. Comparison of baseline patient characteristics between
centers. Table S2. Baseline covariate effects on eGFRcreat+cysC using
linear mixed effects model parameter estimates, 95% confidence intervals
and p-values.
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